{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T19:10:03Z","timestamp":1758568203367,"version":"3.44.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T00:00:00Z","timestamp":1702166400000},"content-version":"am","delay-in-days":404,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.therap.2022.03.008","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T23:10:22Z","timestamp":1650928222000},"page":"635-647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Utilisation de TRUVADA\u00ae en prophylaxie pr\u00e9exposition\u00a0: analyse des bases de vigilance et revue de la litt\u00e9rature"],"prefix":"10.1016","volume":"77","author":[{"given":"Carine","family":"Jacomet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Lebeller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schiestel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6809-6975","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Grandvuillemin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siamak","family":"Davani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5737-5733","authenticated-orcid":false,"given":"Marie-Blanche","family":"Valnet-Rabier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2021","series-title":"VIH\/sida","author":"Sant\u00e9 publique France","key":"10.1016\/j.therap.2022.03.008_bib0005"},{"year":"2022","series-title":"Fiche d\u2019information 2020 \u2014 Derni\u00e8res statistiques sur l\u2019\u00e9tat de l\u2019\u00e9pid\u00e9mie de sida","author":"ONUSIDA","key":"10.1016\/j.therap.2022.03.008_bib0010"},{"year":"2015","series-title":"Recommandation relative \u00e0 la prise en charge \u00e0 titre d\u00e9rogatoire de TRUVADA (emtricitabine\/fumarate de tenofovir disoproxil) dans le cadre d\u2019une recommandation temporaire d\u2019utilisation","author":"HAS","key":"10.1016\/j.therap.2022.03.008_bib0015"},{"year":"2022","series-title":"TRUVADA 200 mg\/245 mg cp pellic","author":"Hoptimal VIDAL","key":"10.1016\/j.therap.2022.03.008_bib0020"},{"year":"2018","series-title":"Bonnes pratiques de pharmacovigilance","author":"ANSM","key":"10.1016\/j.therap.2022.03.008_bib0025"},{"year":"2022","series-title":"MedDRA hierarchy","author":"MedDRA","key":"10.1016\/j.therap.2022.03.008_bib0030"},{"key":"10.1016\/j.therap.2022.03.008_bib0035","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIVprevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2022.03.008_bib0040","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1\u00a0infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2022.03.008_bib0045","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1\u00a0infection","volume":"373","author":"Molina","year":"2015","journal-title":"New Engl J Med"},{"key":"10.1016\/j.therap.2022.03.008_bib0050","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.therap.2022.03.008_bib0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/2050-6511-15-77","article-title":"Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial","volume":"15","author":"Mandala","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.therap.2022.03.008_bib0060","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2022.03.008_bib0065","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/QAI.0000000000001129","article-title":"Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation","volume":"73","author":"Marcus","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.therap.2022.03.008_bib0070","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1097\/QAD.0000000000001939","article-title":"Daily or on-demand oral tenofovir disoproxil fumarate\/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France","volume":"32","author":"Noret","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.therap.2022.03.008_bib0075","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1097\/QAD.0000000000001867","article-title":"Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention","volume":"32","author":"Heffron","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.therap.2022.03.008_bib0080","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/QAD.0000000000001313","article-title":"Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding","volume":"31","author":"Mofenson","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.therap.2022.03.008_bib0085","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.therap.2019.09.004","article-title":"Pharmacovigilance\u2013The next chapter","volume":"74","author":"Moore","year":"2019","journal-title":"Therapies"},{"year":"2015","series-title":"Recommandation relative \u00e0 la prise en charge \u00e0 titre d\u00e9rogatoire de TRUVADA (emtricitabine\/fumarate de tenofovir disoproxil) dans le cadre d\u2019une recommandation temporaire d\u2019utilisation","author":"HAS","key":"10.1016\/j.therap.2022.03.008_bib0090"},{"key":"10.1016\/j.therap.2022.03.008_bib0095","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1097\/QAI.0000000000001781","article-title":"Is on-demand hiv pre-exposure prophylaxis a suitable tool for men who have sex with men who practice chemsex? Results from a substudy of the ANRS-IPERGAY trial","volume":"79","author":"Roux","year":"2018","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722000671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595722000671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:55:07Z","timestamp":1758567307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595722000671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0040595722000671"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2022.03.008","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilisation de TRUVADA\u00ae en prophylaxie pr\u00e9exposition\u00a0: analyse des bases de vigilance et revue de la litt\u00e9rature","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2022.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}